Keele Research Repository
Explore the Repository
Bajpai, R, Muller, SN, Mallen, C, Watson, L, Richette, P, Hider, SL and Roddy, E (2021) Onset of comorbidities and flare patterns within pre-existing morbidity clusters in people with gout: 5-year primary care cohort study. Rheumatology, 61 (1). pp. 407-412. ISSN 1462-0332
![[thumbnail of GOLF-Rheumatology-manuscript-accepted.docx]](https://eprints.keele.ac.uk/style/images/fileicons/text.png)
GOLF-Rheumatology-manuscript-accepted.docx - Accepted Version
Available under License Creative Commons Attribution Non-commercial.
Download (4MB)
Abstract
OBJECTIVE: To investigate the onset of comorbidities and pattern of flares over five years according to baseline comorbidity clusters in people with gout. METHODS: In a prospective primary-care-based cohort study, adults aged ≥18 years with gout, were identified from primary care medical records in 20 general practices across the West Midlands, UK and followed-up over five years. Four clusters of participants have been defined previously according to baseline comorbidity status. The associations of (i) incident comorbidities and (ii) gout flares with baseline cluster membership were estimated using age and sex-adjusted Poisson regression and mixed effects ordinal logistic regression, respectively. RESULTS: The comorbidity with the highest incidence was coronary artery disease (39.2%), followed by hypertension (36.7%), chronic kidney disease stage ≥3 (18.1%), obesity (16.0%), hyperlipidaemia (11.7%), diabetes (8.8%), and cancer (8.4%). There were statistically significant associations observed between cluster membership and incidence of coronary artery disease, hyperlipidaemia, heart failure, and hypertension. In each cluster, nearly one-third of participants reported ≥2 gout flares at each time-point. History of oligo/polyarticular flares (odds ratio [OR]: 2.16; 95% confidence interval [CI]: 1.73-2.70), and obesity (1.66; 1.21-2.25) were associated with increasing flares whereas current use of allopurinol was associated with lower risk (0.42; 0.34-0.53). Cluster membership was not associated with flares. CONCLUSION: Substantial numbers of people in each cluster developed new comorbidities that varies by cluster membership. People also experienced multiple flares over time, but these did not differ between clusters. Clinicians should be vigilant for the development of new comorbidities in people with gout.
Item Type: | Article |
---|---|
Additional Information: | The final version of this accepted manuscript and all relevant information can be found online at; https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/keab283/6179312 |
Uncontrolled Keywords: | gout; comorbidity clusters; gout flares; incidence; CVD risk factors; prospective cohort study |
Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine R Medicine > RC Internal medicine > RC925 Diseases of the musculoskeletal system |
Divisions: | Faculty of Medicine and Health Sciences > School of Primary, Community and Social Care |
Related URLs: | |
Depositing User: | Symplectic |
Date Deposited: | 27 Apr 2021 14:14 |
Last Modified: | 19 Apr 2022 09:31 |
URI: | https://eprints.keele.ac.uk/id/eprint/9430 |